A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor

FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors

(2015) F. Li et al.   Cancer Discovery

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

(2014) N. Javidi-Sharifi et al.   CANCER RESEARCH

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

(2013) Yoon-Koo Kang et al.   LANCET ONCOLOGY

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Mechanisms of FGFR3 actions in endocrine resistant breast cancer

(2011) D.C. Tomlinson et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting mutant fibroblast growth factor receptors in cancer

(2011) Heidi Greulich et al.   TRENDS IN MOLECULAR MEDICINE

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

(2010) Ping Chi et al.   NATURE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY